Table 1.
Clinical characteristics of patients according to CPNE3 in training, validation and training + validation cohort
| Variables | Training cohort (n = 138) | Validation cohort (n = 150) | Training + Validation cohort (n = 288) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Low CPNE3 (%) | High CPNE3 (%) | p value | N | Low CPNE3 (%) | High CPNE3 (%) | p value | N | Low CPNE3 (%) | High CPNE3 (%) | p value | |
| Gender | 0.935 | 0.591 | 0.656 | |||||||||
| Male | 91 | 40 (44.0%) | 51 (56.0%) | 90 | 38 (42.2%) | 52 (57.8%) | 181 | 78 (43.1%) | 103 (56.9%) | |||
| Female | 47 | 21 (44.7%) | 26 (55.3%) | 60 | 28 (46.7%) | 32 (53.3%) | 107 | 49 (45.8%) | 58 (54.2%) | |||
| Age (years) | 0.663 | 0.937 | 0.807 | |||||||||
| < 60 | 65 | 30 (46.2%) | 35 (53.8%) | 71 | 31 (43.7%) | 40 (56.3%) | 136 | 61 (44.9%) | 75 (55.1%) | |||
| ≥ 60 | 73 | 31 (42.5%) | 42 (57.5%) | 79 | 35 (44.3%) | 44 (55.7%) | 152 | 66 (43.4%) | 86 (56.6%) | |||
| Tumor size (cm) | 0.171 | 0.750 | 0.473 | |||||||||
| ≥ 4 | 61 | 23 (37.7%) | 38 (62.3%) | 66 | 30 (45.5%) | 36 (54.5%) | 127 | 53 (41.7%) | 74 (58.3%) | |||
| < 4 | 77 | 38 (49.4%) | 39 (50.6%) | 84 | 36 (42.9%) | 48 (57.1%) | 161 | 74 (46.0%) | 87 (54.0%) | |||
| Differentiation status | 0.192 | 0.184 | 0.063 | |||||||||
| Poor and undifferentiated | 94 | 38 (40.4%) | 56 (59.6%) | 93 | 37 (39.8%) | 56 (60.2%) | 187 | 75 (40.1%) | 112 (59.9%) | |||
| Well + Moderate | 44 | 23 (52.3%) | 21 (47.7%) | 57 | 29 (50.9%) | 28 (49.1%) | 101 | 52 (51.5%) | 49 (48.5%) | |||
| Lauren type | 0.266 | 0.989 | 0.437 | |||||||||
| Intestinal type | 57 | 22 (38.6%) | 35 (61.4%) | 66 | 29 (43.9%) | 37 (56.1%) | 123 | 51 (41.5%) | 72 (58.5%) | |||
| Diffuse type | 81 | 39 (48.1%) | 42 (51.9%) | 84 | 37 (44.0%) | 47 (56.0%) | 165 | 76 (46.1%) | 89 (53.9%) | |||
| Depth of invasion | 0.033 | 0.036 | 0.003 | |||||||||
| T3 + T4 | 86 | 32 (37.2%) | 54 (62.8%) | 87 | 32 (36.8%) | 55 (63.2%) | 173 | 64 (37.0%) | 109 (63.0%) | |||
| T1 + T2 | 52 | 29 (55.8%) | 23 (44.2%) | 63 | 34 (54.0%) | 29 (46.0%) | 115 | 63 (54.8%) | 52 (45.2%) | |||
| Lymph node metastasis | 0.048 | 0.047 | 0.005 | |||||||||
| N1 + N2 + N3 | 104 | 41 (39.4%) | 63 (60.6%) | 114 | 45 (39.5%) | 69 (60.5%) | 218 | 86 (39.4%) | 132 (60.6%) | |||
| N0 | 34 | 20 (58.8%) | 14 (41.2%) | 36 | 21 (58.3%) | 15 (41.7%) | 70 | 41 (58.6%) | 29 (41.4%) | |||
| TNM stage | 0.011 | 0.013 | < 0.001 | |||||||||
| III | 82 | 29 (35.4%) | 53 (64.6%) | 96 | 35 (36.5%) | 61 (63.5%) | 178 | 64 (36.0%) | 114 (64.0%) | |||
| I + II | 56 | 32 (57.1%) | 24 (42.9%) | 54 | 31 (57.4%) | 23 (42.6%) | 110 | 63 (57.3%) | 47 (42.7%) | |||